重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌的临床分析

Clinical Analysis of Recombinant Human Vascular Endostatin Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

目的探讨重组人血管内皮抑素持续静脉泵注联合化疗治疗晚期非小细胞肺癌的近期疗效及安全性。方法回顾性分析我院2016年6月至2020年6月收治的74例晚期非小细胞肺癌患者的临床资料,化疗组予以含铂双药化疗,联合组予以重组人血管内皮抑素持续静脉泵注联合化疗,比较两组的近期疗效与不良反应。结果联合组的客观缓解率、疾病控制率分别为43.24%、91.89%,显著高于化疗组的21.62%、67.57%(P<0.05)。联合组的中位疾病进展时间为6.89个月,显著优于化疗组的4.58个月(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论重组人血管内皮抑素持续静脉泵注联合化疗治疗晚期非小细胞肺癌患者可改善近期疗效,不会显著增加不良反应,安全性较高。

Objective To explore the short-term efficacy and safety of recombinant human vascular endostatin through continuous intravenous pumping combined with chemotherapy in the treatment of advanced non-small cell lung cancer.Methods The clinical data of 74 patients with advanced non-small cell lung cancer admitted to our hospital from June 2016 to June 2020 were retrospectively analyzed.The chemotherapy group was given platinum-containing dual-drug chemotherapy,and the combination group was given recombinant human vascular endostatin through continuous intravenous pumping combined with chemotherapy.The short-term efficacy and adverse reactions were compared between two groups.Results The objective remission rate and disease control rate of the combination group were 43.24%and 91.89%respectively,significantly higher than 21.62%and 67.57%of the chemotherapy group(P<0.05).The median time to progression of the combination group was 6.89 months,significantly better than 4.58 months of the chemotherapy group(P<0.05).No significant difference was found in the incidences of adverse reactions between two groups(P>0.05).Conclusions Recombinant human vascular endostatin through continuous intravenous pumping combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer can improve the short-term efficacy,without significantly increasing adverse reactions,with high safety.